One or more adverse event · Patients with presumed drug‐sensitive TB
1 finding from 1 review
One or more adverse event · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes one or more adverse event compared with standard regimen alone (very low certainty).
1 finding from 1 review
Lost one or more lines of BCVA · patients with myopia
Laser‐assisted in‐situ keratomileusis (LASIK) showed no clear difference in lost one or more lines of BCVA compared with photorefractive keratectomy (PRK) (low certainty).
1 finding from 1 review
Intervention not reported
CLABSI rate more than 12 months · patients with an indwelling device
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Intervention not reported
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
The intervention showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Monoclonal antibody showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with no induction (low certainty).
1 finding from 1 review
Intervention not reported
HIV incidence: CD4 subgroups (350 or more CD4 cells/µL) (observational studies) · Serodiscordant couples
The intervention may leads to lower HIV incidence: CD4 subgroups (350 or more CD4 cells/µL)… (low certainty).
1 finding from 1 review
Intervention not reported
Virologically linked HIV incidence: CD4 subgroups (350 or more CD4 cells/µL) (RCT) · Serodiscordant couples
The intervention leads to lower virologically linked HIV incidence: CD4 subgroups (350 or more CD4… (high certainty).
1 finding from 1 review
Hospital admissions · the management of asthma
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with same dose ICS (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with 1 or more exacerbations requiring oral corticosteroids… compared with daily ICS (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE may leads to lower global state: 2. Requiring 3 or more injections ‐ over 7 days compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review